Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging

American Journal of Kidney Diseases

Volumn 72, Issue 6, 2018, Pages 771-773

  Inker, Lesley A ^a   Heerspink, Hiddo L ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; BIOLOGICAL MARKER;

ALBUMINURIA; BAYES THEOREM; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; EDITORIAL; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); DISEASE EXACERBATION;

ALBUMINURIA; BIOMARKERS; CREATININE; DISEASE PROGRESSION; HUMANS; PROTEINURIA;

EID: 85056568721     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2018.08.017     Document Type: Editorial

References (20)

1. Strippoli, G.F., Craig, J.C., Schena, F.P., The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15:2 (2004), 411–419.
2. Food and Drug Administration. Challenges and Opportunities Report: March 2004. http://wayback.archive-it.org/7993/20180125032208/https://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Accessed September 3, 2018.
3. Echt, D., Liebson, R., Mitchell, N., Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:12 (1991), 781–788.
4. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:21 (2009), 2019–2032.
5. James, W.P., Caterson, I.D., Coutinho, W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:10 (2010), 905–917.
6. Palmer, S.C., Ruospo, M., Teixeira-Pinto, A., et al. The validity of drug effects on proteinuria, albuminuria, serum creatinine, and estimated GFR as surrogate end points for ESKD: a systematic review. Am J Kidney Dis 72:6 (2018), 779–789.
7. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:23 (2012), 2204–2213.
8. Wright, J.T. Jr., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:19 (2002), 2421–2431.
9. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:12 (2001), 861–869.
10. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:12 (2001), 851–860.
11. Inker, L.A., Levey, A.S., Pandya, K., Stoycheff, N., Okparavero, A., Greene, T., Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64:1 (2014), 74–85.
12. Ruggenenti, P., Perna, A., Gherardi, G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:9176 (1999), 359–364.
13. Burzykowski, T., Molenberghs, G., Buyse, M., (eds.) The Evaluation of Surrogate Endpoints, 2005, Springer, New York, NY.
14. Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., Geys, H., The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:1 (2000), 49–68.
15. Inker, L.A., Lambers Heerspink, H.J., Mondal, H., et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis 64:6 (2014), 848–859.
16. Jun, M., Turin, T.C., Woodward, M., et al. Assessing the validity of surrogate outcomes for ESRD: a meta-analysis. J Am Soc Nephrol 26:9 (2015), 2289–2302.
17. Levey, A.S., Inker, L.A., Matsushita, K., et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64:6 (2014), 821–835.
18. Greene, T., Teng, C.C., Inker, L.A., et al. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis 64:6 (2014), 867–879.
19. Lambers-Heerspink, H.J., Kropelin, T.F., Hoekman, J., de Zeeuw, D., Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26:8 (2015), 2055–2064.
20. National Kidney Foundation. Accelerating new clinical trials and treatments for kidney disease. 2018. https://www.kidney.org/news/accelerating-new-clinical-trials-and-treatments-kidney-disease. Accessed July 11, 2018.